These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 2715807

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF, Willemse PH, Sleijfer DT, Uges DR, Postmus PE, Meijer S, Terheggen PM, Mulder NH, de Vries EG.
    J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
    [Abstract] [Full Text] [Related]

  • 4. A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
    Kreisle WH, Alberts DS, List AF, McCloskey T, Plezia P, Peng YM, George M.
    Anticancer Drugs; 1991 Jun; 2(3):251-9. PubMed ID: 1802019
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
    Yang J, Shi Y, Li C, Gui L, Zhao X, Liu P, Han X, Song Y, Li N, Du P, Zhang S.
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):637-46. PubMed ID: 25034977
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
    Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
    [Abstract] [Full Text] [Related]

  • 9. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
    Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, Nomura F, Sakai S.
    J Clin Oncol; 1993 Aug 01; 11(8):1602-8. PubMed ID: 8336196
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 01; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct 01; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 13. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 01; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J.
    Cancer Res; 1987 Jan 15; 47(2):617-23. PubMed ID: 3791246
    [Abstract] [Full Text] [Related]

  • 15. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, Drengler R, Simmons C, Santabarbara P, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1999 Nov 15; 5(11):3369-78. PubMed ID: 10589747
    [Abstract] [Full Text] [Related]

  • 16. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.
    Shepherd FA, Evans WK, Blackstein ME, Fine S, Heathcote J, Langer B, Taylor B, Habal F, Kutas G, Pritchard KI.
    J Clin Oncol; 1987 Apr 15; 5(4):635-40. PubMed ID: 3031227
    [Abstract] [Full Text] [Related]

  • 17. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G.
    J Clin Oncol; 1994 Jan 15; 12(1):141-8. PubMed ID: 8270970
    [Abstract] [Full Text] [Related]

  • 18. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
    Tchekmedyian NS, Egorin MJ, Cohen BE, Kaplan RS, Poplin E, Aisner J.
    Cancer Chemother Pharmacol; 1986 Jan 15; 18(1):33-8. PubMed ID: 3757157
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
    Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW.
    Clin Cancer Res; 2001 Feb 15; 7(2):231-42. PubMed ID: 11234874
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 15; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.